+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Polycystic Kidney Disease Drugs Market - Global Forecast 2026-2032- Product Image
Polycystic Kidney Disease Drugs Market - Global Forecast 2026-2032- Product Image
New

Polycystic Kidney Disease Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674533
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The polycystic kidney disease drugs market is entering a transformative phase, reshaped by advances in precision therapies, evolving regulatory policies, and a dynamic landscape of stakeholder priorities. This report provides senior decision-makers with actionable intelligence and strategic foresight for navigating the complexities and opportunities shaping the future of PKD care.

Market Snapshot: Polycystic Kidney Disease Drugs Market

The global polycystic kidney disease drugs market grew from USD 563.92 million in 2025 to USD 590.09 million in 2026. With a projected CAGR of 4.78%, market value is forecast to reach USD 782.19 million by 2032. This sustained growth is underpinned by innovative drug development, new delivery modalities, and expanded patient access across key geographies. Robust demand emerges as clinical advances and patient-centric delivery models elevate the importance of PKD-specific therapeutics among pharmaceutical stakeholders.

Scope & Segmentation

This report frames a high-resolution view of the PKD market, offering detailed segmentation and coverage across product classes, delivery models, disease categories, distribution channels, and regional approaches:

  • Therapeutic Classes: Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, mTOR Inhibitors, Somatostatin Analogs, Vasopressin Receptor Antagonists, and legacy as well as new mechanism-focused agents.
  • Mode of Administration: Intravenous/injectable options versus oral formulations, each requiring distinct clinical, supply chain, and patient support strategies.
  • Disease Types: Autosomal dominant and autosomal recessive PKD, reflecting varying population needs and clinical pathways for intervention.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies, with each setting presenting unique challenges for logistics and adherence monitoring.
  • End-User Settings: Clinics, hospitals, and homecare environments—each driving differentiated educational, monitoring, and service requirements.
  • Geographic Regions: Americas; Europe, Middle East, and Africa; Asia-Pacific. Each brings differing regulatory, reimbursement, and access dynamics.
  • Technologies: Digital health integration, remote monitoring, and hybrid clinical trial models are increasingly shaping the competitive landscape and enabling data-driven decision-making.

Key Takeaways

  • PKD is gaining prominence on therapeutic and commercial agendas through precision medicine, biomarker-driven strategies, and a shift toward disease modification over symptomatic care.
  • Stakeholders must navigate complex market access, with payers requiring robust real-world evidence and integrated value demonstrations to inform adoption and reimbursement.
  • Strategic alliances between pharmaceutical firms, diagnostic developers, specialty pharmacies, and digital providers are creating bundled care propositions and driving end-to-end solutions for sustained patient engagement.
  • Disease segmentation and regional differences require nuanced approaches, with tailored clinical development, localized engagement strategies, and adaptive pricing models for each market environment.
  • Supply chain resilience and operational excellence remain critical, as recent tariff changes and economic volatility have prompted re-evaluation of sourcing, inventory, and manufacturing partner selection.
  • Investment in patient-centric delivery models and diversified evidence generation is essential for maintaining competitive differentiation and fostering long-term commercial success.

Tariff Impact

The 2025 U.S. tariff realignments created new challenges for pharmaceutical manufacturing and distribution. Manufacturers responded by regionalizing production, developing dual-sourcing strategies, and embedding contract terms to manage tariff risks. These shifts have strengthened supply continuity and fostered more resilient partner ecosystems, influencing procurement and partner selection across the PKD therapeutic landscape.

Methodology & Data Sources

Research for this report combined primary stakeholder interviews with clinical, payer, and supply chain experts, alongside comprehensive secondary review of literature, regulatory updates, trial registries, and public disclosures. Structured frameworks mapped clinical attributes, tariff impacts, and segmentation-driven strategy, with peer validation to ensure reliable, high-quality conclusions.

Why This Report Matters

  • Enables informed investment and portfolio decisions by outlining therapeutic, operational, and market access drivers across regions and segments.
  • Equips leaders to craft resilient supply chains and adaptive commercialization strategies in response to regulatory and economic change.
  • Supports patient-centric program development, leveraging insights on digital integration, evidence generation, and stakeholder collaboration.

Conclusion

Stakeholders seeking durable value in PKD therapeutics must align evidence, operations, and patient-centric offerings amid a changing market. This report delivers a strategic foundation for informed action, underpinned by robust data and actionable recommendations.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Polycystic Kidney Disease Drugs Market, by Drug Type
8.1. Angiotensin II Receptor Blockers
8.2. Angiotensin-Converting Enzyme Inhibitors
8.3. Calcium Channel Blockers
8.4. mTOR Inhibitors
8.5. Somatostatin Analogs
8.6. Vasopressin Receptor Antagonists
9. Polycystic Kidney Disease Drugs Market, by Mode of Administration
9.1. Intravenous (IV)
9.2. Oral
10. Polycystic Kidney Disease Drugs Market, by Disease Type
10.1. Autosomal Dominant Polycystic Kidney Disease
10.2. Autosomal Recessive Polycystic Kidney Disease
11. Polycystic Kidney Disease Drugs Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Polycystic Kidney Disease Drugs Market, by End-User
12.1. Clinics
12.2. Homecare Settings
12.3. Hospitals
13. Polycystic Kidney Disease Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Polycystic Kidney Disease Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Polycystic Kidney Disease Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Polycystic Kidney Disease Drugs Market
17. China Polycystic Kidney Disease Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Apotex Inc.
18.6. Boehringer Ingelheim GmbH
18.7. Centessa Pharmaceuticals Limited
18.8. Eli Lilly and Company
18.9. F. Hoffmann-La Roche AG
18.10. Fresenius Kabi AG
18.11. Galapagos NV
18.12. Kyowa Hakko Kirin Co., Ltd.
18.13. Merck & Co., Inc.
18.14. Mitsubishi Tanabe Pharma Corporation
18.15. Novartis International AG
18.16. Otsuka Pharmaceutical Co., Ltd.
18.17. Pfizer Inc.
18.18. Sanofi S.A.
18.19. Teva Pharmaceutical Industries Ltd.
18.20. Vertex Pharmaceuticals Incorporated
18.21. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 80. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 82. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 83. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 84. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. EUROPE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 86. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 88. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 92. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 94. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 96. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 107. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 109. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. ASEAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 111. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 113. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 115. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. GCC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 117. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 123. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 125. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 127. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. BRICS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 129. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 131. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 133. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. G7 POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 135. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 137. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 139. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. NATO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 144. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 146. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 148. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 149. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 150. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 152. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Polycystic Kidney Disease Drugs market report include:
  • Apotex Inc.
  • Boehringer Ingelheim GmbH
  • Centessa Pharmaceuticals Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Galapagos NV
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 590.09 Million
Forecasted Market Value ( USD ) by 2032 $ 782.19 Million
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Polycystic Kidney Disease Drugs Market Report and Forecast 2025-2034 - Product Image

Polycystic Kidney Disease Drugs Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Polycystic Kidney Disease Drug Pipeline Analysis Report 2025 - Product Image

Polycystic Kidney Disease Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Autosomal Dominant Polycystic Kidney Disease Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035 - Product Image

Autosomal Dominant Polycystic Kidney Disease Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Polycystic Kidney Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Polycystic Kidney Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Chronic Kidney Disease Medication Market - Global Forecast 2026-2032 - Product Image

Chronic Kidney Disease Medication Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From

About the Market

Polycystic Kidney Disease (PKD) is a genetic disorder that affects the kidneys and other organs. It is characterized by the growth of numerous cysts in the kidneys, which can lead to kidney failure. Treatment for PKD includes medications to reduce the size of the cysts, slow their growth, and reduce the risk of complications. The market for drugs to treat PKD is part of the larger market for drugs to treat liver and kidney disorders. These drugs are used to treat a variety of conditions, including PKD, chronic kidney disease, and liver cirrhosis. The market is driven by the increasing prevalence of these disorders, as well as advances in medical technology and the development of new drugs. Companies in the PKD drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.